GeoVax Labs (GOVX)

• Market cap: $15.6M
• 1 day: -9.65%
• 5 days: -8.04%
• 1 month: 9.57%
• 3 months: -33.12%
• 6 months: -56.17%
• Year to date: -58.47%
• 1 year: -26.43%
• 5 years: -97.66%
• 10 years: -97.66%
• Sector: Healthcare
• Industry: Biotechnology

About: Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Employees: 17

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

74% more capital invested

Capital invested by funds: $716K [Q4 2024] → $1.24M (+$528K) [Q1 2025]

5.41% more ownership

Funds ownership: 3.07% [Q4 2024] → 8.48% (+5.41%) [Q1 2025]

5% less funds holding

Funds holding: 19 [Q4 2024] → 18 (-1) [Q1 2025]

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8 677% upside
• Avg. target: $8.50 725% upside
• High target: $9 774% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert	774% upside $9	Buy Maintained	2 May 2025
HC Wainwright & Co. Vernon Bernardino	677% upside $8	Buy Reiterated	16 Apr 2025